Canadian radioisotope developer ARTMS has received $300,000 Canadian ($237,590 U.S.) from Innovate BC to help develop the radioisotope zirconium-89 (Zr-89) for PET for patients who are eligible for immuno-oncology therapies.
This money, along with $600,000 Canadian ($475,000 U.S.) received from other resources, will be used to produce Zr-89 for the radiolabeling of molecular targeting ligands, such as antibodies, that are used in the noninvasive monitoring of the immune system by immuno-PET.
